Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Association between inhaled nitric oxide treatment and long-term pulmonary function in survivors of acute respiratory distress syndrome

Parameter Placebo Inhaled NO P Value
Age, years N 41 51  
  Mean ± SD 47.8 ± 16.7 45.3 ± 15.3 0.494
  Range 18.4 - 84.0 16.8 - 77.9  
Sex, n (%) Male 19 (46%) 25 (49%) 0.836
  Female 22 (54%) 26 (51%)  
Race, n (%) Caucasian 35 (85%) 42 (82%) 0.847
  Black 4 (10%) 5 (10%)  
  Other 2 (5%) 4 (8%)  
Height, cm N 39 51  
  Mean ± SD 168.7 ± 11.4 169.4 ± 9.2 0.912
Weight, kg N 41 51  
  Mean ± SD 85.7 ± 24.1 76.4 ± 19.2 0.049
BW ≥ 35% IBW N 19 (46.3%) 13 (25.5%) 0.028
Causes of ARDS,a n (%)     
Pneumonia   20 (49%) 15 (29%) 0.084
Toxic gas inhalation   0 (0%) 0 (0%) 1.000
Acute pancreatitis   1 (2%) 3 (6%) 0.626
Massive blood transfusion   5 (12%) 10 (20%) 0.404
Fat emboli   1 (2%) 2 (4%) 1.000
Aspiration pneumonitis   9 (22%) 9 (18%) 0.610
Pulmonary contusion   6 (15%) 12 (24%) 0.307
Postpartum ARDS   2 (5%) 0 (0%) 0.196
Multiple trauma   14 (34%) 15 (29%) 0.657
Elective or emergency surgical procedures   9 (22%) 20 (39%) 0.114
Patient History, n (%)     
Preexisting steroid use   3 (7%) 8 (15%) 0.334
Asthma   4 (10%) 5 (10%) 1.000
COPD   6 (15%) 6 (12%) 0.761
Tobacco use   17 (41%) 26 (51%) 0.405
  1. aPatients may have more than one cause of ARDS. ARDS, acute respiratory distress syndrome; BW, body weight; COPD, chronic obstructive pulmonary disorder; IBW, ideal body weight; N, number; NO, nitric oxide.